This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their study of patterns of drug therapy and underlying mortality risk in patients with heart failure, Dr Lee and colleagues¹ concluded that patients with congestive heart failure who have the highest risk of mortality have the lowest likelihood of receiving effective drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). These paradoxical findings may reflect 2 methodological problems in this study.

First, in assessing the prescription rate for a drug on the day of discharge, it is likely that the decision to prescribe a drug was affected by the patient's use of this same drug prior to the index hospitalization. Although patients who were not using these drugs before hospitalization may have them prescribed at discharge, patients using them before admission may not have needed a new prescription from the hospital-based physician. To assess this possible source of bias, the analysis of . . . [Full Text of this Article]

Samy Suissa, PhD
samy.suissa@clinepi.mcgill.ca
Division of Clinical Epidemiology
Royal Victoria Hospital
Montreal, Quebec

RELATED ARTICLES

Risk-Treatment Mismatch for Heart Failure—Reply
Douglas S. Lee, Jack V. Tu, and Andreas Laupacis
JAMA. 2005;294(24):3087-3088.
EXTRACT | FULL TEXT  

Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure
Douglas S. Lee, Jack V. Tu, David N. Juurlink, David A. Alter, Dennis T. Ko, Peter C. Austin, Alice Chong, Therese A. Stukel, Daniel Levy, and Andreas Laupacis
JAMA. 2005;294(10):1240-1247.
ABSTRACT | FULL TEXT